PTN

Business Context and Reporting Period

Company: Palatin Technologies, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2009
Industry: Biopharmaceutical (Clinical Stage)
Overview: Palatin is a biopharmaceutical company developing peptide, peptide mimetic, and small molecule agonist compounds targeting melanocortin and natriuretic peptide receptor systems. Key programs include bremelanotide (sexual dysfunction), PL-3994 (heart failure), and a collaboration with AstraZeneca for obesity and metabolic syndrome treatments. The company has no approved products and has never been profitable.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Composition Shift: Revenue remained relatively flat, but the source shifted entirely to the AstraZeneca collaboration ($11.4 million in 2009 vs. $3.0 million in 2008). Revenue from the terminated King Pharmaceuticals agreement ($8.2 million in 2008) ceased in 2009.
• Expense Reduction: Operating expenses decreased significantly due to a workforce reduction initiated in May 2008. R&D expenses dropped 37% and G&A expenses dropped 23% compared to the prior year.
• Improved Loss Position: Net loss improved by approximately $9.6 million year-over-year, driven by lower operating expenses and a gain on the sale of property and equipment ($0.55 million).
• Cash Burn: Net cash used in operating activities decreased from $20.6 million to $5.4 million, aided by $6.6 million in additional payments from AstraZeneca.

Guidance, Outlook, Risks, and Unusual Items

Outlook and Liquidity

Management believes cash, investments, and expected receipts (including a $2.5 million initial payment from a September 2009 AstraZeneca amendment and $2.8 million net proceeds from an August 2009 registered direct offering) are adequate to fund operations through at least September 30, 2010. The company anticipates incurring additional losses in the future and will require further capital to continue development of bremelanotide, PL-3994, and PL-6983.

Key Risks

• Delisting Risk: The company received notice from NYSE Amex regarding non-compliance with listing standards (stockholders' equity below $4 million and stock price below $0.25). A plan to regain compliance was accepted, but failure to meet standards by June 23, 2010, could result in delisting.
• Financing Needs: The company has an accumulated deficit of $207.4 million and relies on equity financings and collaboration payments. Future funding may not be available on acceptable terms, potentially leading to significant dilution or curtailment of operations.
• Development Uncertainty: All product candidates are in clinical or preclinical stages. Success depends on regulatory approval, which is uncertain, and the ability to secure reimbursement.

Unusual Items

• Income Tax Benefit: The company recognized a $1.7 million income tax benefit in 2009 (vs. $1.3 million in 2008) solely from the sale of New Jersey state net operating loss carryforwards. The company maintains a full valuation allowance against federal deferred tax assets.
• Gain on Sale: A one-time gain of $0.55 million was recorded from the sale of property and equipment.

Investor Verification Checklist

• Liquidity Runway: Verify the receipt of the $2.5 million initial payment from the September 2009 AstraZeneca amendment and the sufficiency of cash to reach the projected September 2010 funding horizon.
• Listing Compliance: Monitor progress toward regaining NYSE Amex compliance (stockholders' equity and stock price) to avoid delisting to the OTC market.
• Clinical Milestones: Track the initiation of Phase 2 clinical studies for subcutaneous bremelanotide and PL-3994, which are projected to commence in the first half of calendar 2010 pending funding.
• Dilution Impact: Assess the impact of the August 2009 registered direct offering and potential future equity raises on existing shareholders, given the low stock price.
• Revenue Concentration: Note that 100% of 2009 revenue was derived from AstraZeneca, creating significant dependency on this single partner.